Panelists discuss how economic considerations in immunoglobulin A (IgA) nephropathy medication management vary dramatically across chronic kidney disease (CKD) stages, with early intervention costs ...

Panelists discuss how promising ongoing and upcoming clinical trials may reshape sequencing strategies in ALK+ non–small cell lung cancer (NSCLC).

Panelists discuss how immunoglobulin A (IgA) nephropathy’s progressive nature and significant economic impact demand a shift in payer perspective toward investing in disease-modifying therapies that, ...

Panelists discuss how to approach patient education after progression on an ALK inhibitor, address real-world challenges during therapy transitions, and determine best options for patients progressing ...

Defining "value" in cancer care goes beyond survival and should encompass patient quality of life metrics, said Coral Omene, MD, PhD, of Robert Wood Johnson Medical School.

A meta-analysis suggests allogeneic stem cell transplantation (allo-SCT) should not be recommended following first-line ...

The findings are notable in part because therapies have already been approved to target C5aR1 in other diseases.

While citing overwhelming barriers patients in rural areas face when accessing care, providers noted the potential of telehealth to improve access in a survey.

TP53 aberrations and circulating tumor DNA burden were found to be predictors of poor outcomes in high-risk patients with ...

The findings provide insight into which patients may have favorable or inferior responses to immunotherapy for small cell ...

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration.

The Congressional Budget Office estimates the package would add $2.4 trillion to the national deficit over a decade and leave ...